efavirenz Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 989 154598-52-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • efavirenz
  • stocrin
  • (-)-Efavirenz
  • sustiva
Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta are not inhibited by efavirenz.
  • Molecular weight: 315.68
  • Formula: C14H9ClF3NO2
  • CLOGP: 3.73
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -4.57
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 27.15 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 17, 1998 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maternal exposure during pregnancy 862.79 22.85 474 10066 155165 53183361
Abortion spontaneous 789.94 22.85 309 10231 46326 53292200
Stillbirth 621.82 22.85 163 10377 6634 53331892
Viral mutation identified 556.97 22.85 119 10421 1955 53336571
Virologic failure 518.71 22.85 114 10426 2150 53336376
Abortion induced 477.97 22.85 147 10393 10679 53327847
Pregnancy 464.30 22.85 189 10351 31252 53307274
Exposure during pregnancy 423.09 22.85 278 10262 124582 53213944
Immune reconstitution inflammatory syndrome 406.53 22.85 115 10425 6231 53332295
Foetal exposure during pregnancy 364.63 22.85 164 10376 34551 53303975
Drug resistance 304.74 22.85 123 10417 19839 53318687
Normal newborn 268.78 22.85 86 10454 7093 53331433
Pathogen resistance 268.03 22.85 84 10456 6476 53332050
Congenital umbilical hernia 212.64 22.85 42 10498 455 53338071
Live birth 167.03 22.85 74 10466 14985 53323541
Blood HIV RNA increased 164.86 22.85 37 10503 768 53337758
Lipodystrophy acquired 157.62 22.85 41 10499 1609 53336917
Caesarean section 141.90 22.85 69 10471 17251 53321275
Birth mark 128.60 22.85 24 10516 187 53338339
Premature delivery 110.15 22.85 67 10473 26037 53312489
Treatment noncompliance 95.73 22.85 67 10473 32968 53305558
Fanconi syndrome acquired 94.31 22.85 25 10515 1056 53337470
Lactic acidosis 92.97 22.85 69 10471 37184 53301342
Pregnancy with implant contraceptive 91.95 22.85 29 10511 2277 53336249
Viral load increased 91.09 22.85 26 10514 1449 53337077
Cerebellar ataxia 83.70 22.85 22 10518 899 53337627
Pulmonary tuberculosis 81.08 22.85 32 10508 4849 53333677
Immune reconstitution inflammatory syndrome associated tuberculosis 79.02 22.85 18 10522 400 53338126
Pregnancy on contraceptive 72.59 22.85 21 10519 1228 53337298
Autoimmune hepatitis 70.70 22.85 34 10506 8284 53330242
Foetal death 61.17 22.85 32 10508 9315 53329211
CD4 lymphocytes decreased 58.02 22.85 19 10521 1682 53336844
Drug interaction 56.51 22.85 130 10410 219199 53119327
Ataxia 54.99 22.85 35 10505 14702 53323824
Premature baby 54.65 22.85 39 10501 19762 53318764
Ectopic pregnancy 52.42 22.85 20 10520 2767 53335759
Malaria 51.87 22.85 12 10528 286 53338240
Pain 51.70 22.85 26 10514 588372 52750154
Hepatitis fulminant 50.72 22.85 21 10519 3598 53334928
Cleft lip and palate 48.88 22.85 12 10528 371 53338155
Anaemia 48.58 22.85 142 10398 276576 53061950
Tuberculosis 45.61 22.85 28 10512 11043 53327483
Portal hypertension 43.51 22.85 19 10521 3709 53334817
Twin pregnancy 42.79 22.85 14 10526 1235 53337291
Cholestatic liver injury 40.46 22.85 16 10524 2435 53336091
Drug level increased 40.43 22.85 33 10507 20388 53318138
Mitochondrial cytopathy 40.07 22.85 10 10530 331 53338195
Lipoatrophy 39.90 22.85 10 10530 337 53338189
Rash maculo-papular 38.85 22.85 38 10502 29711 53308815
Fatigue 36.65 22.85 55 10485 730451 52608075
Premature rupture of membranes 35.45 22.85 18 10522 4922 53333604
Hepatomegaly 34.26 22.85 24 10516 11807 53326719
Nephropathy toxic 33.58 22.85 21 10519 8551 53329975
Arthralgia 33.51 22.85 23 10517 439760 52898766
Encephalopathy 32.15 22.85 38 10502 36770 53301756
Abnormal dreams 31.85 22.85 22 10518 10579 53327947
Congenital anomaly 31.84 22.85 12 10528 1605 53336921
Cytomegalovirus chorioretinitis 31.61 22.85 12 10528 1637 53336889
Cardiac malposition 31.18 22.85 6 10534 56 53338470
Gene mutation 30.73 22.85 11 10529 1272 53337254
Abdominal discomfort 30.19 22.85 4 10536 221058 53117468
Abortion threatened 29.69 22.85 9 10531 619 53337907
HIV-associated neurocognitive disorder 29.53 22.85 7 10533 186 53338340
Hepatic displacement 28.22 22.85 5 10535 28 53338498
Joint swelling 28.17 22.85 6 10534 234632 53103894
Maternal drugs affecting foetus 28.01 22.85 16 10524 5530 53332996
Retinal toxicity 27.69 22.85 10 10530 1187 53337339
Spinocerebellar disorder 27.26 22.85 5 10535 35 53338491
Meningitis cryptococcal 26.80 22.85 10 10530 1301 53337225
Pregnancy on oral contraceptive 26.31 22.85 10 10530 1369 53337157
Diastasis recti abdominis 26.15 22.85 5 10535 45 53338481
Pre-eclampsia 26.11 22.85 18 10522 8629 53329897
Hypertriglyceridaemia 26.11 22.85 16 10524 6288 53332238
HIV infection 25.92 22.85 8 10532 584 53337942
Isosporiasis 25.76 22.85 5 10535 49 53338477
Genital prolapse 25.76 22.85 5 10535 49 53338477
Type III hyperlipidaemia 25.73 22.85 4 10536 8 53338518
Peripheral swelling 25.29 22.85 5 10535 206103 53132423
Polydactyly 24.37 22.85 7 10533 399 53338127
Congenital acrochordon 24.19 22.85 5 10535 69 53338457
Multiple-drug resistance 23.84 22.85 12 10528 3223 53335303
Nightmare 23.78 22.85 23 10517 17728 53320798
Drug ineffective 23.53 22.85 83 10457 817162 52521364
Hydrocephalus 23.52 22.85 14 10526 5222 53333304
Acute stress disorder 23.29 22.85 6 10534 226 53338300

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Depression 994.41 14.76 682 21112 96378 32395354
Immune reconstitution inflammatory syndrome 850.73 14.76 297 21497 9262 32482470
Virologic failure 650.63 14.76 194 21600 3593 32488139
Viral mutation identified 626.11 14.76 179 21615 2840 32488892
Drug interaction 594.56 14.76 728 21066 217457 32274275
Lipodystrophy acquired 539.92 14.76 167 21627 3515 32488217
Pathogen resistance 441.82 14.76 184 21610 9326 32482406
Abnormal dreams 284.82 14.76 131 21663 8433 32483299
Drug resistance 259.09 14.76 172 21622 22793 32468939
Mitochondrial toxicity 254.14 14.76 87 21707 2543 32489189
Foetal exposure during pregnancy 229.84 14.76 203 21591 41098 32450634
Progressive external ophthalmoplegia 202.53 14.76 62 21732 1256 32490476
Eyelid ptosis 172.50 14.76 81 21713 5461 32486271
Loss of personal independence in daily activities 157.44 14.76 136 21658 26697 32465035
Lipoatrophy 149.65 14.76 42 21752 619 32491113
Congenital umbilical hernia 141.39 14.76 38 21756 472 32491260
Viral load increased 133.03 14.76 57 21737 3093 32488639
CD4 lymphocytes decreased 127.93 14.76 50 21744 2140 32489592
Pulmonary tuberculosis 125.39 14.76 63 21731 4926 32486806
Osteoporosis 110.85 14.76 80 21714 12102 32479630
Hyperlipidaemia 106.95 14.76 84 21710 14427 32477305
Fanconi syndrome acquired 106.35 14.76 44 21750 2186 32489546
Treatment failure 101.28 14.76 128 21666 39035 32452697
Gynaecomastia 96.83 14.76 65 21729 8754 32482978
Diplopia 96.30 14.76 79 21715 14433 32477299
Retinal toxicity 90.71 14.76 26 21768 415 32491317
Psychiatric decompensation 90.14 14.76 35 21759 1471 32490261
Depression suicidal 88.97 14.76 34 21760 1368 32490364
Tearfulness 85.91 14.76 35 21759 1671 32490061
HIV infection 85.13 14.76 36 21758 1890 32489842
Blood HIV RNA increased 84.27 14.76 34 21760 1583 32490149
Renal tubular disorder 84.03 14.76 49 21745 5153 32486579
Meningitis cryptococcal 80.38 14.76 36 21758 2173 32489559
Hyperlactacidaemia 71.94 14.76 37 21757 3037 32488695
Off label use 70.77 14.76 61 21733 306259 32185473
Paranoia 67.92 14.76 57 21737 10742 32480990
Nightmare 67.76 14.76 62 21732 13104 32478628
Treatment noncompliance 67.29 14.76 87 21707 27115 32464617
Kaposi's sarcoma 65.63 14.76 25 21769 997 32490735
Extraocular muscle paresis 64.57 14.76 21 21773 521 32491211
Ophthalmoplegia 63.73 14.76 27 21767 1424 32490308
Hepatic fibrosis 60.88 14.76 35 21759 3583 32488149
Death 58.19 14.76 105 21689 382412 32109320
Fanconi syndrome 57.86 14.76 27 21767 1793 32489939
Pneumonia 57.23 14.76 94 21700 355158 32136574
Hypertriglyceridaemia 54.79 14.76 46 21748 8673 32483059
Immune reconstitution inflammatory syndrome associated tuberculosis 53.87 14.76 18 21776 487 32491245
Proteinuria 50.12 14.76 60 21734 17295 32474437
Birth mark 48.35 14.76 14 21780 232 32491500
Nephropathy toxic 47.81 14.76 49 21745 11897 32479835
Tuberculosis 46.67 14.76 42 21752 8687 32483045
Fall 46.54 14.76 38 21756 196163 32295569
Febrile neutropenia 45.47 14.76 12 21782 119554 32372178
Renal impairment 45.21 14.76 150 21644 91822 32399910
Genotype drug resistance test positive 43.31 14.76 22 21772 1759 32489973
Depressive symptom 42.43 14.76 22 21772 1836 32489896
Hypophosphataemia 42.20 14.76 40 21754 8835 32482897
Drug abuse 42.19 14.76 3 21791 80240 32411492
Atrial fibrillation 42.00 14.76 13 21781 116691 32375041
Hypotension 41.88 14.76 50 21744 216060 32275672
HIV-associated neurocognitive disorder 41.86 14.76 14 21780 380 32491352
Multiple-drug resistance 41.85 14.76 28 21766 3747 32487985
Nervous system disorder 41.27 14.76 49 21745 14000 32477732
Malignant neoplasm progression 41.08 14.76 3 21791 78493 32413239
Blood triglycerides increased 39.70 14.76 49 21745 14570 32477162
Lactic acidosis 39.12 14.76 76 21718 33460 32458272
Glycosuria 38.87 14.76 19 21775 1399 32490333
Hydrocele 38.72 14.76 22 21772 2202 32489530
Dyslipidaemia 38.54 14.76 34 21760 6849 32484883
Portal hypertension 37.67 14.76 27 21767 4037 32487695
Drug-induced liver injury 37.66 14.76 62 21732 24001 32467731
Retroviral rebound syndrome 36.82 14.76 7 21787 13 32491719
Skull malformation 36.75 14.76 13 21781 419 32491313
Psychomotor skills impaired 36.31 14.76 22 21772 2481 32489251
Constipation 35.94 14.76 20 21774 126353 32365379
Polydactyly 35.08 14.76 17 21777 1228 32490504
Lymph node tuberculosis 34.69 14.76 13 21781 495 32491237
Osteopenia 33.51 14.76 27 21767 4805 32486927
CD4 lymphocytes abnormal 33.47 14.76 9 21785 112 32491620
Mycobacterium avium complex infection 33.22 14.76 22 21772 2895 32488837
Blood lactic acid increased 33.14 14.76 30 21764 6251 32485481
Hepatitis 33.05 14.76 58 21736 23635 32468097
Psychotic disorder 32.95 14.76 57 21737 22963 32468769
Suicidal ideation 32.50 14.76 76 21718 38007 32453725
Aspartate aminotransferase increased 32.31 14.76 108 21686 66321 32425411
Pain 31.64 14.76 48 21746 187508 32304224
Cytomegalovirus chorioretinitis 31.21 14.76 23 21771 3589 32488143
Acquired immunodeficiency syndrome 31.14 14.76 12 21782 494 32491238
Lymphadenopathy 31.13 14.76 61 21733 27021 32464711
Testicular germ cell tumour mixed 31.01 14.76 7 21787 39 32491693
Hepatosplenomegaly 29.62 14.76 23 21771 3880 32487852
Dyspnoea 29.37 14.76 134 21660 361911 32129821
Hepatic cirrhosis 28.61 14.76 45 21749 16764 32474968
Developmental hip dysplasia 28.61 14.76 10 21784 311 32491421
Mycobacterium avium complex immune restoration disease 28.39 14.76 7 21787 60 32491672
Fatigue 28.32 14.76 130 21664 350571 32141161
Gamma-glutamyltransferase increased 28.00 14.76 63 21731 30719 32461013
Neurosyphilis 27.89 14.76 7 21787 65 32491667
Hepatitis B 27.18 14.76 27 21767 6314 32485418
Hepatitis C 27.01 14.76 39 21755 13479 32478253
Vanishing bile duct syndrome 26.95 14.76 12 21782 714 32491018
Cryptococcosis 26.92 14.76 17 21777 2063 32489669
Hepatotoxicity 26.53 14.76 47 21747 19290 32472442
Cachexia 26.36 14.76 28 21766 7081 32484651
Osteonecrosis 26.24 14.76 43 21751 16579 32475153
Malaria 25.74 14.76 9 21785 280 32491452
Peripheral swelling 25.70 14.76 7 21787 68338 32423394
Anal cancer 25.17 14.76 10 21784 447 32491285
Renal tubular dysfunction 24.94 14.76 10 21784 458 32491274
Histoplasmosis disseminated 24.72 14.76 13 21781 1117 32490615
Megakaryocytes increased 24.70 14.76 6 21788 48 32491684
Diabetes mellitus 24.27 14.76 76 21718 45097 32446635
Night blindness 24.24 14.76 8 21786 208 32491524
Mitochondrial cytopathy 24.10 14.76 8 21786 212 32491520
Osteomalacia 23.84 14.76 12 21782 941 32490791
Alanine aminotransferase increased 23.83 14.76 110 21684 78369 32413363
Psychomotor retardation 23.71 14.76 18 21776 2937 32488795
Intracranial pressure increased 23.71 14.76 20 21774 3793 32487939
Talipes 23.43 14.76 15 21779 1863 32489869
Drug ineffective 23.38 14.76 156 21638 383321 32108411
Infection 23.22 14.76 14 21780 84701 32407031
Sickle cell disease 22.58 14.76 7 21787 148 32491584
Sleep disorder 22.40 14.76 53 21741 26699 32465033
Renal tubular acidosis 22.35 14.76 15 21779 2017 32489715
Liver transplant 22.13 14.76 17 21777 2823 32488909
Hepatomegaly 22.11 14.76 31 21763 10426 32481306
Blood alkaline phosphatase increased 22.03 14.76 59 21735 32073 32459659
Nephrolithiasis 21.62 14.76 53 21741 27301 32464431
Oral candidiasis 21.59 14.76 33 21761 11994 32479738
Liver disorder 21.57 14.76 58 21736 31596 32460136
Nasopharyngitis 21.38 14.76 8 21786 63779 32427953
Tubulointerstitial nephritis 21.18 14.76 43 21751 19534 32472198
Back pain 21.14 14.76 26 21768 111027 32380705
Meningitis tuberculous 21.11 14.76 10 21784 687 32491045
Pulmonary oedema 21.02 14.76 3 21791 46264 32445468
Hepatic function abnormal 21.00 14.76 72 21722 44768 32446964
Influenza 20.87 14.76 3 21791 46011 32445721
Limb deformity 20.73 14.76 9 21785 504 32491228
Blood pressure increased 20.54 14.76 14 21780 79340 32412392
Hypercholesterolaemia 20.49 14.76 26 21768 7948 32483784
Polyneuropathy chronic 20.47 14.76 5 21789 41 32491691
Hospitalisation 20.43 14.76 4 21790 48967 32442765
Chronic obstructive pulmonary disease 20.30 14.76 4 21790 48749 32442983
Strabismus congenital 20.26 14.76 5 21789 43 32491689
Nodular regenerative hyperplasia 20.15 14.76 10 21784 761 32490971
Synostosis 19.95 14.76 6 21788 114 32491618
Mitochondrial myopathy 19.89 14.76 7 21787 222 32491510
Syphilis 19.33 14.76 9 21785 594 32491138
Amylase increased 19.25 14.76 22 21772 6033 32485699
Blood oestrogen decreased 19.23 14.76 4 21790 14 32491718
Toxoplasma serology positive 19.01 14.76 4 21790 15 32491717
Korsakoff's syndrome 18.93 14.76 3 21791 0 32491732
Interstitial lung disease 18.88 14.76 10 21784 64991 32426741
Congenital eyelid malformation 18.84 14.76 5 21789 59 32491673
Hydrops foetalis 18.77 14.76 7 21787 263 32491469
Product use issue 18.75 14.76 6 21788 52771 32438961
Osteoporotic fracture 18.68 14.76 11 21783 1177 32490555
Product use in unapproved indication 18.14 14.76 19 21775 87185 32404547
C-reactive protein increased 17.94 14.76 5 21789 48097 32443635
Fat redistribution 17.86 14.76 6 21788 165 32491567
Neck deformity 17.86 14.76 5 21789 73 32491659
Platelet count decreased 17.73 14.76 31 21763 114560 32377172
Disease risk factor 17.61 14.76 4 21790 23 32491709
Lipohypertrophy 17.45 14.76 7 21787 321 32491411
Cardiac failure congestive 17.08 14.76 19 21775 84833 32406899
Drug screen false positive 17.04 14.76 9 21785 780 32490952
Hepatic steatosis 16.94 14.76 35 21759 16098 32475634
Elbow synostosis 16.94 14.76 4 21790 28 32491704
Blood cholesterol increased 16.88 14.76 37 21757 17720 32474012
Congenital bowing of long bones 16.81 14.76 4 21790 29 32491703
Cleft lip and palate 16.58 14.76 7 21787 366 32491366
Liver injury 16.53 14.76 32 21762 14042 32477690
Congenital tuberculosis 16.47 14.76 4 21790 32 32491700
Pneumocystis jirovecii pneumonia 16.47 14.76 38 21756 18832 32472900
Blood phosphorus decreased 16.46 14.76 15 21779 3151 32488581
Eyelid ptosis congenital 16.25 14.76 5 21789 103 32491629
Neuropsychiatric syndrome 16.16 14.76 5 21789 105 32491627
Porphyria acute 16.07 14.76 5 21789 107 32491625
Beta 2 microglobulin urine increased 15.98 14.76 5 21789 109 32491623
Meconium ileus 15.95 14.76 4 21790 37 32491695
Splenomegaly 15.90 14.76 32 21762 14445 32477287
Pneumonia aspiration 15.88 14.76 4 21790 41152 32450580
Cerebral toxoplasmosis 15.86 14.76 11 21783 1561 32490171
Disease progression 15.84 14.76 21 21773 86841 32404891
Oesophageal candidiasis 15.69 14.76 17 21777 4397 32487335
Trisomy 18 15.66 14.76 6 21788 243 32491489
Product dose omission issue 15.64 14.76 28 21766 102547 32389185
Castleman's disease 15.58 14.76 4 21790 41 32491691
Viraemia 15.54 14.76 10 21784 1253 32490479
Extrapulmonary tuberculosis 15.41 14.76 5 21789 123 32491609
Hepatic necrosis 15.35 14.76 16 21778 3959 32487773
Optic disc haemorrhage 15.24 14.76 4 21790 45 32491687
Fibrous histiocytoma 15.22 14.76 5 21789 128 32491604
Transaminases increased 15.22 14.76 44 21750 24984 32466748
Pain in extremity 15.13 14.76 36 21758 118865 32372867
Protein S deficiency 15.12 14.76 5 21789 131 32491601
Inappropriate schedule of product administration 14.93 14.76 6 21788 45819 32445913
Subacute sclerosing panencephalitis 14.93 14.76 4 21790 49 32491683
Hereditary optic atrophy 14.77 14.76 3 21791 9 32491723
Premature baby 14.76 14.76 36 21758 18482 32473250

Pharmacologic Action:

SourceCodeDescription
ATC J05AG03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Non-nucleoside reverse transcriptase inhibitors
ATC J05AR06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175460 Non-Nucleoside Analog
FDA EPC N0000175463 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D065695 Cytochrome P-450 CYP2B6 Inducers
MeSH PA D065689 Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA D065688 Cytochrome P-450 CYP2C9 Inhibitors
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190118 Cytochrome P450 3A Inducers
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:53756 reverse transcriptase inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Prevention of HIV Infection after Exposure off-label use
Osteomalacia contraindication 4598005 DOID:10573
Hypophosphatemia contraindication 4996001
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Depressive disorder contraindication 35489007
Fanconi syndrome contraindication 40488004 DOID:1062
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Chronic type B viral hepatitis contraindication 61977001
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Chronic hepatitis C contraindication 128302006
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Paranoid disorder contraindication 191667009
Steatosis of liver contraindication 197321007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.6 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8716264 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9457036 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9744181 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
Cholesterol 24-hydroxylase Enzyme Kd 6.10 CHEMBL
Cytochrome P450 3A4 Enzyme INHIBITOR IC50 4.76 IUPHAR
Reverse transcriptase/RNaseH Enzyme INHIBITOR Ki 8.52 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein INHIBITOR IC50 8.30 WOMBAT-PK
Reverse transcriptase Enzyme IC50 8.89 CHEMBL
Reverse transcriptase protein Unclassified Ki 8.07 CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Unclassified IC50 8.46 CHEMBL

External reference:

IDSource
4021133 VUID
N0000148587 NUI
D00896 KEGG_DRUG
4021133 VANDF
C0674428 UMLSCUI
CHEBI:119486 CHEBI
EFZ PDB_CHEM_ID
CHEMBL223228 ChEMBL_ID
DB00625 DRUGBANK_ID
C098320 MESH_SUPPLEMENTAL_RECORD_UI
64139 PUBCHEM_CID
11287 IUPHAR_LIGAND_ID
7718 INN_ID
JE6H2O27P8 UNII
195084 RXNORM
11884 MMSL
210786 MMSL
7492 MMSL
d04355 MMSL
007651 NDDF
116078005 SNOMEDCT_US
387001004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUSTIVA HUMAN PRESCRIPTION DRUG LABEL 1 0056-0470 CAPSULE, GELATIN COATED 50 mg ORAL NDA 31 sections
SUSTIVA HUMAN PRESCRIPTION DRUG LABEL 1 0056-0474 CAPSULE, GELATIN COATED 200 mg ORAL NDA 31 sections
SUSTIVA HUMAN PRESCRIPTION DRUG LABEL 1 0056-0510 TABLET, FILM COATED 600 mg ORAL NDA 31 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 3 0093-5234 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
Efavirenz HUMAN PRESCRIPTION DRUG LABEL 1 0378-2233 TABLET, FILM COATED 600 mg ORAL ANDA 26 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 15584-0101 TABLET, FILM COATED 600 mg ORAL NDA 34 sections
Efavirenz Human Prescription Drug Label 1 31722-504 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 33342-138 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
Efavirenz, emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 3 42385-915 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 42385-928 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 42385-929 TABLET, FILM COATED 400 mg ORAL ANDA 30 sections
Efavirenz HUMAN PRESCRIPTION DRUG LABEL 1 42543-889 TABLET 600 mg ORAL ANDA 26 sections
SYMFI LO HUMAN PRESCRIPTION DRUG LABEL 3 49502-425 TABLET, FILM COATED 400 mg ORAL NDA 32 sections
SYMFI HUMAN PRESCRIPTION DRUG LABEL 3 49502-475 TABLET, FILM COATED 600 mg ORAL NDA 31 sections
Efavirenz HUMAN PRESCRIPTION DRUG LABEL 1 51407-382 TABLET 600 mg ORAL ANDA 26 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 53808-0208 TABLET, FILM COATED 600 mg ORAL NDA 31 sections
SUSTIVA HUMAN PRESCRIPTION DRUG LABEL 1 54868-4668 TABLET, FILM COATED 600 mg ORAL NDA 29 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 54868-5643 TABLET, FILM COATED 600 mg ORAL NDA 31 sections
Atripla Access HUMAN PRESCRIPTION DRUG LABEL 3 61958-1601 TABLET, FILM COATED 600 mg ORAL EXPORT ONLY 34 sections
Efavirenz HUMAN PRESCRIPTION DRUG LABEL 1 64380-889 TABLET 600 mg ORAL ANDA 18 sections
Efavirenz Human Prescription Drug Label 1 64980-406 CAPSULE 50 mg ORAL ANDA 29 sections
Efavirenz Human Prescription Drug Label 1 64980-407 CAPSULE 200 mg ORAL ANDA 29 sections
Efavirenz Human Prescription Drug Label 1 65862-049 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Efavirenz Human Prescription Drug Label 1 65862-104 CAPSULE 50 mg ORAL ANDA 29 sections
Efavirenz Human Prescription Drug Label 1 65862-105 CAPSULE 100 mg ORAL ANDA 29 sections
Efavirenz Human Prescription Drug Label 1 65862-106 CAPSULE 200 mg ORAL ANDA 29 sections
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 65862-497 TABLET, FILM COATED 600 mg ORAL ANDA 30 sections
efavirenz, emtricitabine and tenofovir disoproxil fumarate HUMAN PRESCRIPTION DRUG LABEL 3 69097-210 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Efavirenz HUMAN PRESCRIPTION DRUG LABEL 1 69097-301 TABLET, FILM COATED 600 mg ORAL ANDA 26 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 70518-0341 TABLET, FILM COATED 600 mg ORAL NDA 33 sections